Pelthos Therapeutics Inc.
PTHS
$26.90
$0.602.28%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 27.70M | 16.80M | 7.41M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.70M | 16.80M | 7.41M | -- | -- |
| Cost of Revenue | 6.88M | 5.22M | 3.45M | 1.41M | 907.00K |
| Gross Profit | 20.82M | 11.58M | 3.95M | -1.41M | -907.00K |
| SG&A Expenses | 61.92M | 42.45M | 25.52M | 7.53M | 6.56M |
| Depreciation & Amortization | 2.59M | 1.56M | 679.00K | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.38M | 49.22M | 29.66M | 8.94M | 7.47M |
| Operating Income | -43.68M | -32.43M | -22.25M | -8.94M | -7.47M |
| Income Before Tax | -58.98M | -50.71M | -24.05M | -9.04M | -7.36M |
| Income Tax Expenses | -7.39M | -7.39M | -465.00K | -- | -- |
| Earnings from Continuing Operations | -51.59 | -43.32 | -23.58 | -9.04 | -7.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.59M | -43.32M | -23.58M | -9.04M | -7.36M |
| EBIT | -43.68M | -32.43M | -22.25M | -8.94M | -7.47M |
| EBITDA | -37.38M | -25.79M | -15.01M | -- | -- |
| EPS Basic | -20.65 | -20.77 | -17.09 | -14.71 | -12.40 |
| Normalized Basic EPS | -14.31 | -14.39 | -10.78 | -9.20 | -7.75 |
| EPS Diluted | -20.65 | -20.77 | -17.09 | -14.71 | -12.40 |
| Normalized Diluted EPS | -14.31 | -14.39 | -10.78 | -9.20 | -7.75 |
| Average Basic Shares Outstanding | 10.17M | 7.47M | 4.92M | 2.44M | 2.37M |
| Average Diluted Shares Outstanding | 10.17M | 7.47M | 4.92M | 2.44M | 2.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |